Computer-Aided Vaccine Design Using Deductive Multiscale Simulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development methods for viruses like HPV, Hepatitis E, and Chikungunya rely on traditional wet-laboratory approaches, which are costly and time-consuming, involving mutation, assembly, and immunogenicity testing, lacking an efficient and cost-effective computer-aided design strategy.
Innovation Solution
A computer-aided vaccine design approach using advanced nanoparticle simulation, bioinformatics, and standard nanoparticle synthesis methods, integrating a deductive multiscale simulator (DMS) to model virus-like particles (VLPs), predict immunogenicity, and design candidate vaccines through computational synthesis and validation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional wet-laboratory approaches are used for vaccine development, then comprehensive experimental validation is achieved, but development cost and time increase significantly
Solution Approach 1:
The patent performs preliminary computational actions (molecular dynamics simulations, free energy calculations, epitope identification) before wet-laboratory experimentation. This allows researchers to pre-screen candidate VLPs and identify promising candidates computationally, reducing the number of expensive and time-consuming experimental trials needed while maintaining validation reliability.
Solution Approach 2:
The patent creates computational copies (virtual models) of virus-like particles through detailed molecular simulations. These digital twins allow researchers to study VLP behavior, stability, and immunogenicity in silico before physical experimentation, significantly reducing development time while preserving the ability to validate key findings experimentally.
2Reliability
If traditional wet-laboratory approaches are used for vaccine development, then comprehensive experimental validation is achieved, but development cost increases
Solution Approach 1:
The patent performs preliminary computational actions (molecular dynamics simulations, free energy calculations, epitope identification) before wet-laboratory experimentation. This allows researchers to pre-screen candidate VLPs and identify promising candidates computationally, reducing the number of expensive and time-consuming experimental trials needed while maintaining validation reliability.
Solution Approach 2:
The patent creates computational copies (virtual models) of virus-like particles through detailed molecular simulations. These digital twins allow researchers to study VLP behavior, stability, and immunogenicity in silico before physical experimentation, significantly reducing development time while preserving the ability to validate key findings experimentally.
3Productivity
If computational methods are used to screen VLP candidates, then development time and cost are reduced, but screening accuracy may be compromised
Solution Approach 1:
The patent employs multiple computational parameters and metrics to assess VLP candidates, including binding free energy (ΔG), root-mean-square fluctuation (RMSF), radius of gyration (Rg), and epitope accessibility. By changing and combining multiple parameters rather than relying on a single metric, the method maintains screening efficiency while improving prediction accuracy through multi-parameter validation.
Solution Approach 2:
The patent implements feedback loops where computational predictions guide subsequent simulations and refinements. Molecular dynamics simulations provide feedback on VLP stability, which informs further epitope screening and candidate selection. This iterative feedback process enhances prediction accuracy while maintaining computational efficiency.
Data Source
AI summary
Virus-like particle (hereinafter sometimes VLP)-based strategies for developing vaccines against human viruses. Computer models of the VLPs are modified by the addition to the computer models of computer models of viral materials of the viruses against which the vaccines are being developed.